Association of tissue inhibitor of metalloproteinase 2 with non-alcoholic fatty liver disease in metabolic syndrome

Arch Physiol Biochem. 2019 Dec;125(5):441-446. doi: 10.1080/13813455.2018.1481095. Epub 2018 Jun 18.

Abstract

The aim of this case-control study was to assess TIMP2 level in subjects with or without metabolic syndrome (MetS) and to associate levels with non-alcoholic fatty liver changes (NAFLD). Thirty-three MetS subjects and 55 controls were recruited. Anthropometric data, lipid and glucose profile, TIMP2 and liver ultrasound was performed. High TIMP2 was seen in MetS group (145.28 ± 23.11 pg/ml) versus controls (19.06 ± 1.19 pg/ml; p < .001). Serum cholesterol, triglyceride, LDL-c and glucose levels were significantly higher in MetS subjects (p < .05). MetS individuals (72.72%) showed positive fatty liver changes versus 14.5% controls. Elevated TIMP2 positively correlated with waist circumference, body fat, blood glucose and NAFLD. Furthermore, every unit rise in waist circumference and TIMP2 and a unit decrease in HDL were associated with higher odds of developing NAFLD (p < .05). There may be concurrent relationship between TIMP2 and NAFLD in MetS that requires further evaluation to improve risk assessment and early diagnosis of MetS.

Keywords: NAFLD; Obesity; TIMP2; metabolic syndrome; metalloproteinase.

MeSH terms

  • Adult
  • Blood Glucose / metabolism
  • Case-Control Studies
  • Cholesterol, LDL / blood
  • Female
  • Humans
  • Male
  • Metabolic Syndrome / complications*
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / complications*
  • Non-alcoholic Fatty Liver Disease / enzymology*
  • Tissue Inhibitor of Metalloproteinase-2 / metabolism*
  • Triglycerides / blood
  • Young Adult

Substances

  • Blood Glucose
  • Cholesterol, LDL
  • Triglycerides
  • Tissue Inhibitor of Metalloproteinase-2